ISRCTN53968814 https://doi.org/10.1186/ISRCTN53968814

# Medical Research Council fourth non-small cell lung cancer radiotherapy study: clinical trial of radiotherapy for good-performance-status patients with inoperable non-small cell lung cancer too large in volume for radical radiotherapy

| Submission date | Recruitment status | [_] Prospectively registered |
|---|---|---|
| 19/08/2002 | No longer recruiting | [_] Protocol |
| **Registration date** | **Overall study status** | [_] Statistical analysis plan |
| 19/08/2002 | Completed | [X] Results |
| **Last Edited** | **Condition category** | [_] Individual participant data |
| 15/11/2019 | Cancer | |

**Plain English summary of protocol**
Not provided at time of registration

## Contact information

**Type(s)**
Scientific

**Contact name**
Dr - -

**Contact details**
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

## Additional identifiers

**Protocol serial number**
LU13

# Study information

### Scientific Title
Medical Research Council fourth non-small cell lung cancer radiotherapy study: clinical trial of radiotherapy for good-performance-status patients with inoperable non-small cell lung cancer too large in volume for radical radiotherapy

### Study objectives
Not provided at time of registration.

### Ethics approval required
Old ethics approval format

### Ethics approval(s)
Not provided at time of registration.

### Study design
Randomised controlled trial

### Primary study design
Interventional

### Study type(s)
Treatment

### Health condition(s) or problem(s) studied
Lung (non-small cell) cancer

### Interventions
1. Radiotherapy Regimen A: A total dose of 17 Gy given as two fractions of 8.5 Gy with an interval of one week between the fractions.
2. Radiotherapy Regimen B: A total dose of 39 Gy given as thirteen fractions of 3 Gy during three weeks in daily fractions five days per week.

Radiotherapy should start within two weeks of randomisation. If the patient has superior vena cava obstruction, a course of steroids may be given during the period of radiotherapy.

### Intervention Type
Other

### Phase
Not Specified

### Primary outcome(s)
Not provided at time of registration.

### Key secondary outcome(s))
Not provided at time of registration.

### Completion date

31/12/2002

# Eligibility

### Key inclusion criteria
1. Primarily untreated, microscopically confirmed non-small cell lung cancer
2. Performance status World Health Organisation (WHO) grade zero to two
3. Disease too advanced for radical radiotherapy
4. Either sex, any age

### Participant type(s)
Patient

### Healthy volunteers allowed
No

### Age group
Other

### Sex
All

### Key exclusion criteria
1. Previous surgery, radiotherapy or chemotherapy for non-small cell lung cancer
2. Other previous concomitant malignant disease. Except previous basal cell carcinoma or in situ carcinoma of the cervix
3. Evidence of distant metastases outside of the locoregional volume

### Date of first enrolment
01/01/2002

### Date of final enrolment
31/12/2002

# Locations

### Countries of recruitment
United Kingdom

England

### Study participating centre
### UKCCCR Register Co-ordinator
London
United Kingdom
NW1 2DA

# Sponsor information

### Organisation
Medical Research Council (MRC) (UK)

# Funder(s)

### Funder type
Research council

### Funder Name
Medical Research Council (MRC) (UK)

### Alternative Name(s)
Medical Research Council (United Kingdom), UK Medical Research Council, Medical Research Committee and Advisory Council, MRC

### Funding Body Type
Government organisation

### Funding Body Subtype
National government

### Location
United Kingdom

# Results and Publications

### Individual participant data (IPD) sharing plan

### IPD sharing plan summary
Not provided at time of registration

### Study outputs

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 01/10/1994 | 15/11/2019 | Yes | No |